KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,465 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALVGet Free Report) CEO Benjamin L. Palleiko sold 7,465 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $11.53, for a total value of $86,071.45. Following the completion of the sale, the chief executive officer now directly owns 224,547 shares of the company’s stock, valued at $2,589,026.91. The sale was disclosed in a legal filing with the SEC, which is available through this link.

KalVista Pharmaceuticals Stock Up 3.1 %

Shares of NASDAQ:KALV opened at $12.04 on Tuesday. The business’s 50 day moving average is $11.62 and its 200 day moving average is $12.06. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.21 and a 12-month high of $16.88. The stock has a market cap of $507.97 million, a price-to-earnings ratio of -3.82 and a beta of 0.90.

KalVista Pharmaceuticals (NASDAQ:KALVGet Free Report) last posted its quarterly earnings data on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). As a group, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. increased its stake in KalVista Pharmaceuticals by 11.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock valued at $44,373,000 after buying an additional 383,435 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of KalVista Pharmaceuticals by 9.6% in the third quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock valued at $16,684,000 after acquiring an additional 151,808 shares in the last quarter. Capital World Investors purchased a new stake in shares of KalVista Pharmaceuticals during the first quarter valued at approximately $17,370,000. StemPoint Capital LP lifted its holdings in KalVista Pharmaceuticals by 174.4% during the first quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock worth $13,770,000 after acquiring an additional 737,886 shares during the period. Finally, Affinity Asset Advisors LLC boosted its position in KalVista Pharmaceuticals by 56.1% in the third quarter. Affinity Asset Advisors LLC now owns 278,292 shares of the specialty pharmaceutical company’s stock worth $2,680,000 after purchasing an additional 100,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on KALV shares. HC Wainwright cut their target price on KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Needham & Company LLC reissued a “buy” rating and set a $35.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, May 1st.

Get Our Latest Stock Analysis on KALV

About KalVista Pharmaceuticals

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Articles

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.